| PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice V Villanueva, W D’Souza, H Goji, DW Kim, C Liguori, R McMurray, I Najm, ... Journal of Neurology 269 (4), 1957-1977, 2022 | 36 | 2022 |
| Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures V Villanueva, M Holtkamp, N Delanty, J Rodriguez-Uranga, R McMurray, ... Journal of Neurology 264, 2232-2248, 2017 | 34 | 2017 |
| Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy M Holtkamp, R McMurray, M Bagul, R Sousa, E Kockelmann Acta Neurologica Scandinavica 134 (1), 76-82, 2016 | 33 | 2016 |
| Treatment of adults with Lennox–Gastaut syndrome: further analysis of efficacy and safety/tolerability of rufinamide R McMurray, P Striano Neurology and Therapy 5, 35-43, 2016 | 29 | 2016 |
| Rufinamide for the treatment of Lennox‐Gastaut syndrome: evidence from clinical trials and clinical practice P Striano, R McMurray, E Santamarina, M Falip Epileptic Disorders 20 (1), 13-29, 2018 | 25 | 2018 |
| Real-world data on rufinamide treatment in patients with Lennox–Gastaut syndrome: Results from a European noninterventional registry study M Nikanorova, C Brandt, S Auvin, R McMurray Epilepsy & Behavior 76, 63-70, 2017 | 24 | 2017 |
| Dibenzazepine agents in epilepsy: how does eslicarbazepine acetate differ? C Lawthom, J Peltola, R McMurray, E Dodd, V Villanueva Neurology and therapy 7, 195-206, 2018 | 23 | 2018 |
| Eslicarbazepine acetate in post‐stroke epilepsy: clinical practice evidence from Euro‐Esli F Sales, J Chaves, R McMurray, R Loureiro, H Fernandes, V Villanueva Acta Neurologica Scandinavica 142 (6), 563-573, 2020 | 17 | 2020 |
| Effectiveness and safety/tolerability of eslicarbazepine acetate in epilepsy patients aged≥ 60 versus< 60 years: a subanalysis from the Euro-Esli Study C Lawthom, P Bermejo, D Campos, R McMurray, V Villanueva Neurology and Therapy 8, 491-504, 2019 | 15 | 2019 |
| Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset … H Hamer, M Baulac, R McMurray, E Kockelmann Seizure 34, 66-73, 2016 | 15 | 2016 |
| Novel seizure outcomes in patients with lennox‐gastaut syndrome: post hoc analysis of seizure‐free days in rufinamide study 303 S Auvin, B Williams, R McMurray, D Kumar, C Perdomo, M Malhotra Epilepsia Open 4 (2), 275-280, 2019 | 14 | 2019 |
| Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: clinical practice findings from the Euro-Esli study CP Doherty, S Rheims, G Assenza, G Boero, J Chaves, R McMurray, ... Journal of the Neurological Sciences 402, 88-99, 2019 | 11 | 2019 |
| Perampanel for the treatment of patients with myoclonic seizures in clinical practice: evidence from the PERMIT study W D'Souza, T Alsaadi, J Montoya, M Carreño, C Di Bonaventura, ... Seizure 100, 56-66, 2022 | 8 | 2022 |
| Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice R Rocamora, J Peltola, G Assenza, R McMurray, V Villanueva Seizure 75, 121-128, 2020 | 8 | 2020 |
| Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro‐Esli M Holtkamp, N Delanty, F Sales, J Serratosa, R McMurray, V Villanueva Acta Neurologica Scandinavica 139 (1), 49-63, 2019 | 8 | 2019 |
| Anticonvulsant add-on therapy with Eslicarbazepine acetate: results of the EPOS-study in adults in Germany FP Losch, M Holtkamp, R McMurray, D Lendemans, E Kockelmann Der Nervenarzt 87, 1094-1099, 2016 | 6 | 2016 |
| Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: evidence from the PERMIT study C Liguori, E Santamarina, A Strzelczyk, JJ Rodríguez-Uranga, R Shankar, ... Frontiers in Neurology 14, 1120150, 2023 | 4 | 2023 |
| Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial P Striano, R McMurray Epilepsia 56, 211-211, 2015 | 3 | 2015 |
| Predictors of seizure freedom, response and retention after 12 months of treatment with eslicarbazepine acetate: A post-hoc analysis of the Euro-Esli study F Sales, N Delanty, O Mecarelli, M Holtkamp, R McMurray, R Loureiro, ... Epilepsy Research 174, 106653, 2021 | 2 | 2021 |
| Effectiveness and tolerability of perampanel in epilepsy patients treated in routine clinical practice: a global pooled analysis study (1640) W D’Souza, E Trinka, T Wu, I Najm, M Malhotra, LY Ngo, R McMurray, ... Neurology 96 (15 Supplement), 2021 | 2 | 2021 |
